A Swedish national cohort study of 14,694 people with bipolar disorder found that semaglutide use was associated with a lower risk of psychiatric hospitalization, with no concerning safety signals such as suicidality. Published in Acta Psychiatrica Scandinavica, the study analyzed 2009-2024 registry data from patients using diabetes medications. This is the first study to evaluate GLP-1 receptor agonists in people with bipolar disorder, despite frequent co-occurrence of diabetes, obesity, and bipolar disorder.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.